RNAi-mediated knockdown of AURKB and EGFR shows enhanced therapeutic efficacy in prostate tumor regression

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Aurora B kinase (AURKB) and epidermal growth factor receptor 1 (EGFR) are serine/threonine and tyrosine kinases, respectively.
• Both AURKB and EGFR are frequently overexpressed in various epithelial cancers, including hormone-refractory prostate cancer.

Purpose of the Study:

• To investigate the down-regulation of AURKB and EGFR, individually and in combination, in prostate cancer cells.
• To evaluate the therapeutic efficacy of targeting AURKB and EGFR in preclinical models of prostate cancer.

Main Methods:

• Utilized siRNA technology for the targeted down-regulation of AURKB and EGFR expression in prostate cancer cell lines (PC3 and LNCaP).
• Assessed the effects of gene silencing on cell proliferation and apoptosis in vitro.
• Evaluated the impact of AURKB and EGFR knockdown on tumor growth and regression in an in vivo athymic nude mouse model.

Main Results:

• AURKB and EGFR were efficiently down-regulated in a dose-dependent manner by siRNA.
• Combined AURKB and EGFR siRNA significantly inhibited PC3 cell proliferation and induced apoptosis in vitro.
• Individual knockdown of AURKB or EGFR inhibited prostate tumor growth in vivo; combined knockdown led to tumor regression, with 40% of mice becoming tumor-free.

Conclusions:

• Targeting AURKB and EGFR, particularly in combination, demonstrates significant therapeutic potential for prostate cancer.
• The efficacy of AURKB-EGFR combination therapy is correlated with endogenous expression levels and is more pronounced in androgen-independent cancer cells.
• Combined AURKB-EGFR knockdown offers a promising strategy for inducing tumor regression and achieving tumor eradication in prostate cancer models.